127 related articles for article (PubMed ID: 2475099)
1. Diffuse large cell lymphoma: a teaching hospital experience.
Marks DI; Sheridan WP; Ellis DW; Boyd AW; Morstyn G; Green MD; Fox RM
Aust N Z J Med; 1989 Apr; 19(2):159-61. PubMed ID: 2475099
[No Abstract] [Full Text] [Related]
2. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.
Ghetie MA; Podar EM; Gordon BE; Pantazis P; Uhr JW; Vitetta ES
Int J Cancer; 1996 Sep; 68(1):93-6. PubMed ID: 8895546
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells.
Hurwitz CA; Gore SD; Stone KD; Civin CI
Leukemia; 1992 Apr; 6(4):233-9. PubMed ID: 1375301
[TBL] [Abstract][Full Text] [Related]
4. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
5. Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: implications for surveillance of residual leukemia.
Smith RG; Kitchens RL
Blood; 1989 Jul; 74(1):312-9. PubMed ID: 2473798
[TBL] [Abstract][Full Text] [Related]
6. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
7. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation.
Offit K; Parsa NZ; Filippa D; Jhanwar SC; Chaganti RS
Blood; 1992 Nov; 80(10):2594-9. PubMed ID: 1384792
[TBL] [Abstract][Full Text] [Related]
8. Consolidation anti-CD22 fractionated radioimmunotherapy with
Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
[TBL] [Abstract][Full Text] [Related]
9. [Intravascular large B-cell lymphoma: report of a case].
Yu GH; Qu GM; Yao WD; Lang ZQ; Wang W
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):488-9. PubMed ID: 19781202
[No Abstract] [Full Text] [Related]
10. Conjunctival lymphoma in a child.
Waisbourd M; Leibovitch I; Sayar D; Elhasid R
Cornea; 2011 May; 30(5):598-9. PubMed ID: 21107252
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological and molecular genetic characteristics of childhood diffuse large B cell lymphoma].
Huang H; Yang WP; Xu HY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):209-11. PubMed ID: 22780976
[No Abstract] [Full Text] [Related]
12. [Primary cutaneous follicle centre lymphoma: report of a case].
Rong YF; He LM; Zhang YS; Feng YZ
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):769-70. PubMed ID: 24447559
[No Abstract] [Full Text] [Related]
13. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
[No Abstract] [Full Text] [Related]
14. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Chen DB; Wang Y; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
[No Abstract] [Full Text] [Related]
15. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects.
Renner C; Trümper L; Pfreundschuh M
Leukemia; 1997 Apr; 11 Suppl 2():S55-9. PubMed ID: 9178842
[TBL] [Abstract][Full Text] [Related]
16. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
Browne P; Petrosyan K; Hernandez A; Chan JA
Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
[TBL] [Abstract][Full Text] [Related]
17. Malignant lymphoma with myxoid stroma: a new pattern in need of recognition.
Tse CC; Chan JK; Yuen RW; Ng CS
Histopathology; 1991 Jan; 18(1):31-5. PubMed ID: 1707393
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 antibody therapy for B-cell lymphomas.
Maloney DG
N Engl J Med; 2012 May; 366(21):2008-16. PubMed ID: 22621628
[No Abstract] [Full Text] [Related]
19. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
20. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
[No Abstract] [Full Text] [Related]
[Next] [New Search]
